Lophora Closes Bridge Round to Strengthen Global Patent Portfolio and prepare for Phase I
Founded by initial investments from BII (Novo Nordisk Foundation), Vækstfonden (EIFO) and Innovation Fund Denmark, Lophora has received additional support of ~US$1M from a syndicate of family offices and experienced biotech investors. The new investment allows Lophora to strengthen its global composition of matter patent portfolio and produce GMP-grade drug product of its first-in-class lead candidate LPH-5, which is ready to enter Phase I studies.